Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
TREMELIMUMAB ACTL 300 MG 15 ML VIAL (OTHER 12203919) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 2, 2026 , from http://ppman.hank.ai/transparency/procedure/12203919/by-state?code_type=OTHER
“TREMELIMUMAB ACTL 300 MG 15 ML VIAL (OTHER 12203919) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/12203919/by-state?code_type=OTHER. Accessed
July 2, 2026 .
“TREMELIMUMAB ACTL 300 MG 15 ML VIAL (OTHER 12203919) by State,” HANK Price Transparency ,
accessed July 2, 2026 ,
http://ppman.hank.ai/transparency/procedure/12203919/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
12203919 — Tremelimumab Actl 300 Mg 15 Ml Vial
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$98,164
National median
$40,933 – $126,050
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 12203919 (OTHER), with interquartile range
State Median p25 p75
IL $98,164 $40,933 $126,050